13D Filings
Home
FAQ
Kezar Life Sciences, Inc.
KZR
Amendment
Ownership

0.00%

Total Shares

0

Issuer CIK

1645666

Event Date

May 10, 2026

Accepted

May 13, 2026, 04:15 PM

SEC EDGARView Original Filing
Reporting Persons (7)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
TANG CAPITAL MANAGEMENT, LLC
Other
0.00%000
KEVIN TANG
Individual
0.00%000
TANG CAPITAL PARTNERS, LP
Partnership
0.00%000
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Partnership
0.00%000
TANG CAPITAL PARTNERS III, INC
CO
0.00%000
TANG CAPITAL PARTNERS IV, INC
CO
0.00%000
CONCENTRA BIOSCIENCES, LLC
Other
0.00%000
Disclosure Items (3)

Security Title

Common Stock, par value $0.001 per share

Issuer Name

Kezar Life Sciences, Inc.

Issuer Address

4000 Shoreline Court, South San Francisco, CA, 94080

Item 4 of the Original Schedule 13D is hereby amended to add the following: Closing of the Merger: On May 11, 2026, the Issuer completed its merger with Aurinia Pharma U.S., Inc. ("Parent") and Parent's wholly-owned subsidiary, Aurinia Merger Sub, Inc. ("Merger Sub") pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Issuer, in accordance with the General Corporation Law of the State of Delaware, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on May 11, 2026, each issued and outstanding share of the Issuer's Common Stock was cancelled.

Percentage of Class

The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons do not own any shares of the Issuer's Common Stock.

Number of Shares

See item 5(a) above.

Transactions

Except as described in this Amendment No. 2, there have been no transactions in the Issuer's Common Stock during the past 60 days by the Reporting Persons.

Shareholders

No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.

Date of 5% Ownership

The Reporting Persons ceased to be beneficial owners of 5% or more of the Issuer's Common Stock on May 11, 2026.